The paediatric vaccine market valuation is US$ 54,130.1 million in 2023. The market is predicted to grow at a remarkable CAGR of 13.1% to reach a valuation of US$ 184,706.7 million by 2033. Thus, it showcases that the paediatric vaccine market is due for significant growth over the coming years.
Production and Distribution Analysis in the Paediatric Vaccine Market
| Attributes | Details |
|---|---|
| Paediatric Vaccine Market Value for 2023 | US$ 54,130.1 million |
| Projected Market Value for 2033 | US$ 184,706.7 million |
| Value-based CAGR for 2023 to 2033 | 13.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The paediatric vaccine market grew at a rate of 9.7% during the historical period from 2017 to 2022. Increasing awareness about vaccines, the development of vaccines for children, the rising rate of approval for vaccines, and other factors are all suggested to contribute to the market's rapid growth.
Diseases that attack weakened immune systems, such as Rubella, Hepatitis A, and Hepatitis B, continue to pose threats to children. The demand for paediatric vaccines will continue unabated over the forecast period due to the prevalence of these diseases.
| Historical CAGR | 9.7% |
|---|---|
| Forecast CAGR | 13.1% |
The arrival of the pandemic resulted in a growing demand for paediatric vaccines, which greatly boosted the market. The paediatric vaccine market expanded to US$ 48,816.7 million in 2022.
The pandemic also had a negative impact on the paediatric market. While the Covid-19 vaccine helped the market, other paediatric vaccines experienced lower demand. The Covid-19 vaccines were also not suitable for children in the initial stages, losing out on a huge section of the market. However, the pandemic reinforced the need for proper preventative care in the minds of the people.
Principal Consultant
The paediatric vaccine market is expected to grow at a robust rate of 13.1% CAGR over the forecast period. By 2033, the market is predicted to reach US$ 184,706.7 million.
Innovations with the help of technology are predicted to drive the market for paediatric vaccines. Gene vaccines are developed with the help of new technology, infusing DNA and RNA to combat diseases. Gene vaccines have found acceptance during the historical period, and their growth is expected to continue over the forecast period.
The rollout of vaccines for COVID-19 during the historical period initially excluded children from the list of beneficiaries. However, vaccines are being tested and approved for use on children, and thus the paediatric market is able to target a big section of the population.
While monovalent vaccines continue to enjoy a major share of the market, there has been a growing demand for bivalent or combination vaccines. Combination vaccines combine the effects of two vaccines in one go and are thus recognized to save people’s time. As the number of vaccines grows, combination vaccines are also expected to increase in popularity due to their multi-effectiveness.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The paediatric vaccine market can be divided into the following segments: indication, technology, vaccine type, and end users. Shedding light on these segments is useful in determining the nature of the products and users of the vaccines. These insights also shed light on the preferences of users and manufacturers in the paediatric vaccine market.
The pneumococcal vaccine is the most represented of the vaccines by indication. It enjoyed a 32.5% share in the global market in 2022, up from 31.9% in 2021.
The pneumococcal vaccine is recommended to be given to children by no less an authority than the World Health Organization (WHO). The use of pneumococcal vaccine can help prevent cases of pneumonia, meningitis, and sepsis. Thus, the pneumococcal vaccine is in high demand.
The pneumococcal vaccine is expected to grow rapidly over the forecast period. As efforts are being expanded toward shielding children from harmful diseases, the value and demand of pneumococcal vaccines are experiencing an upward trajectory.
| Attributes | Details |
|---|---|
| Top Indication | Pneumococcal Vaccine |
| Market Share in 2022 | 32.5% |
Conjugate vaccines make up the highest market share in terms of technology in the paediatric vaccines market. In 2022, they made up 32.8 % of the market share, up from 32% in 2021.
Paediatric vaccine producers rely on conjugate vaccines. They have a track record of being effective, like the Hib conjugate vaccine, which has fought meningitis convincingly. Another example is the typhoid conjugate vaccine, which has proven to reduce the risk of typhoid fever and is WHO-recommended. Conjugate vaccines are thus expected to grow rapidly over the forecast period.
| Attributes | Details |
|---|---|
| Top Technology | Conjugate Vaccines |
| Market Share in 2022 | 32.8% |
Monovalent vaccines are more popular than multivalent vaccines. They held a share of 73.6 % of the market in 2022.
Monovalent vaccines have historically been the most produced of all vaccines. Their growth is expected to continue over the forecast period. Monovalent vaccine shielding against mumps, rubella, and COVID-19 is predicted to be higher in demand over the projected period. However, multivalent vaccines are also rising. Quadrivalent vaccines are used against the threat of influenza, while new bivalent vaccines have been approved to combat COVID-19.
| Attributes | Details |
|---|---|
| Top Type | Monovalent Vaccine |
| Market Share in 2022 | 73.6% |
Institutional health centres are the most common end-use sector for paediatric vaccines. They enjoyed a significant share of the market in 2022, taking up 72.9% of the share, up from 72.3% in 2021.
Institutional health centres have qualified staff for the administration of paediatric vaccines and are trusted institutions. They also have the support of the government.
| Attributes | Details |
|---|---|
| Top End-use Sector | Institutional health centers |
| Market Share in 2022 | 72.9% |
In the paediatric vaccine market, North America and Europe continue to lead the market share. In 2022, North America held 24.3% of the market share, while Europe held sway over 26.1%.
The USA is the leading market in North America. It is poised to continue its positive upward trajectory over the forecast period. In Europe, meanwhile, the United Kingdom market is expected to grow at a rapid rate.
Some of the highest growth rates are predicted for the Asia-Pacific. The Chinese and Indian paediatric vaccine markets are expected to boom during the forecast period. The high population in these countries is a significant factor contributing to the rising demand for vaccines.
| Countries | Market Share in 2022 |
|---|---|
| United States | 17.9% |
| China | 19.6% |
| India | 19.2% |
| United Kingdom | 16.1% |
| Australia | 9.4% |
The United States continues to hold the largest market share in the North American market. In the overall paediatric vaccines market, the United States held a market share of 17.9% in 2022.
Healthcare facilities have improved drastically, thus providing better avenues for the distribution of paediatric vaccines. There has also been a growing consciousness among the people of the importance of vaccinations. People are aware of the risks posed to children due to various diseases and are thus willing to resort to vaccines to ward them off. There has also been an increased investment in research and development, which is aiding the cause of paediatric vaccines in the United States.
China experienced the effects of Covid-19 severely. Thus, there is a high volume of paediatric patients. In these circumstances, there is a growing demand for paediatric vaccines. In addition to Covid-19, threats of meningitis, diphtheria, pertussis, and tetanus are also present. This is leading to the rising demand for vaccines like the meningococcal vaccine and the DTaP vaccine.
China’s paediatric vaccine market is expected to soar during the forecast period. It held a 19.6% share of the global market in 2022.
There is also a high volume of paediatric patients in India. As the population is booming, the number of people at risk of diseases is also increasing. Thus, the paediatric vaccine market is being propelled by the rising number of childbirths in India.
The Indian market held a share of 19.2% of the global market in 2022. Leading campaigns by the government are helping the paediatric vaccine market in India. There is a raised acknowledgment of the need for paediatric vaccines, and the market is expected to grow at a substantial rate over the forecast period.
The United Kingdom market is another market where campaigns have played a key role. Initiatives have been taken to increase immunization among the people. The government has launched programs to increase the number of vaccinated children.
The United Kingdom paediatric vaccine market held a share of 16.1% of the global market in 2022. The steps taken by the health authorities in the United Kingdom will drive the market growth during the projected period.
In the Australian market, paediatric vaccines are in demand as there is fear over the outbreak of diseases. Steps have been taken to make the paediatric population more immunized through vaccines.
The Australian paediatric vaccine market held a share of 9.4% of the global market in 2022. Some of the diseases the Australian people want paediatric vaccines for are COVID-19, Tetanus, and Hepatitis B.
The paediatric vaccine suppliers are increasingly leveraging the benefits of collaborations. Partnerships with healthcare institutions, mergers with other manufacturers in the market, acquisitions, and collaborative strategies are some of the strategies adopted by paediatric vaccine suppliers.
The paediatric vaccines market does not feature manufacturers that are highly dominant. Instead, the market is fragmented, with several key players enjoying their share of the pie. The producers of paediatric vaccines are also receiving increasing approvals from health regulators to distribute their vaccines.
Recent Developments in the Paediatric Vaccine Market
Key Companies in the Paediatric Vaccine Market
The paediatric vaccine market is projected to grow at a rate of 13.1% through 2033.
Pfizer Inc., GlaxoSmithKline Plc, and Merck & Co. Inc. are some of the prominent companies in the market.
The market is predicted to reach a valuation of US $ 184,706.7 million by 2033.
The pneumococcal vaccine is the leading vaccine type by indication.
Rising health awareness among the people is the major factor driving the demand for paediatric vaccines.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Indication, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Indication, 2023 to 2033
5.3.1. Pneumococcal Conjugate Vaccine
5.3.2. DTP Vaccine
5.3.3. Influenza
5.3.4. Meningococcal Vaccine
5.3.5. Polio Vaccine
5.3.6. Rotavirus Vaccine
5.3.7. MMR Vaccine
5.3.8. Varicella Virus Vaccine
5.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Technology, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Technology, 2023 to 2033
6.3.1. Live or Attenuated Vaccine
6.3.2. Inactivated or Killed Vaccine
6.3.3. Toxoid Vaccine
6.3.4. Conjugate Vaccine
6.3.5. Subunit Vaccine
6.3.6. Recombinant Vector Vaccine
6.4. Y-o-Y Growth Trend Analysis By Technology, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Technology, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Vaccine
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Vaccine, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Vaccine, 2023 to 2033
7.3.1. Monovalent Vaccines
7.3.2. Multivalent Vaccines
7.4. Y-o-Y Growth Trend Analysis By Vaccine, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Vaccine, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End User, 2023 to 2033
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Institutional Health Centers
8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. U.S.
10.2.1.2. Canada
10.2.2. By Indication
10.2.3. By Technology
10.2.4. By Vaccine
10.2.5. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Indication
10.3.3. By Technology
10.3.4. By Vaccine
10.3.5. By End User
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Indication
11.2.3. By Technology
11.2.4. By Vaccine
11.2.5. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Indication
11.3.3. By Technology
11.3.4. By Vaccine
11.3.5. By End User
11.4. Key Takeaways
12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. U.K.
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Indication
12.2.3. By Technology
12.2.4. By Vaccine
12.2.5. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Indication
12.3.3. By Technology
12.3.4. By Vaccine
12.3.5. By End User
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Indication
13.2.3. By Technology
13.2.4. By Vaccine
13.2.5. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Indication
13.3.3. By Technology
13.3.4. By Vaccine
13.3.5. By End User
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Indication
14.2.3. By Technology
14.2.4. By Vaccine
14.2.5. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Indication
14.3.3. By Technology
14.3.4. By Vaccine
14.3.5. By End User
14.4. Key Takeaways
15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Indication
15.2.3. By Technology
15.2.4. By Vaccine
15.2.5. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Indication
15.3.3. By Technology
15.3.4. By Vaccine
15.3.5. By End User
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Indication
16.2.3. By Technology
16.2.4. By Vaccine
16.2.5. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Indication
16.3.3. By Technology
16.3.4. By Vaccine
16.3.5. By End User
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. U.S.
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Indication
17.1.2.2. By Technology
17.1.2.3. By Vaccine
17.1.2.4. By End User
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Indication
17.2.2.2. By Technology
17.2.2.3. By Vaccine
17.2.2.4. By End User
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Indication
17.3.2.2. By Technology
17.3.2.3. By Vaccine
17.3.2.4. By End User
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Indication
17.4.2.2. By Technology
17.4.2.3. By Vaccine
17.4.2.4. By End User
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Indication
17.5.2.2. By Technology
17.5.2.3. By Vaccine
17.5.2.4. By End User
17.6. U.K.
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Indication
17.6.2.2. By Technology
17.6.2.3. By Vaccine
17.6.2.4. By End User
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Indication
17.7.2.2. By Technology
17.7.2.3. By Vaccine
17.7.2.4. By End User
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Indication
17.8.2.2. By Technology
17.8.2.3. By Vaccine
17.8.2.4. By End User
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Indication
17.9.2.2. By Technology
17.9.2.3. By Vaccine
17.9.2.4. By End User
17.10. Poland
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Indication
17.10.2.2. By Technology
17.10.2.3. By Vaccine
17.10.2.4. By End User
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Indication
17.11.2.2. By Technology
17.11.2.3. By Vaccine
17.11.2.4. By End User
17.12. Czech Republic
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Indication
17.12.2.2. By Technology
17.12.2.3. By Vaccine
17.12.2.4. By End User
17.13. Romania
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Indication
17.13.2.2. By Technology
17.13.2.3. By Vaccine
17.13.2.4. By End User
17.14. India
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Indication
17.14.2.2. By Technology
17.14.2.3. By Vaccine
17.14.2.4. By End User
17.15. Bangladesh
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Indication
17.15.2.2. By Technology
17.15.2.3. By Vaccine
17.15.2.4. By End User
17.16. Australia
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Indication
17.16.2.2. By Technology
17.16.2.3. By Vaccine
17.16.2.4. By End User
17.17. New Zealand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Indication
17.17.2.2. By Technology
17.17.2.3. By Vaccine
17.17.2.4. By End User
17.18. China
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Indication
17.18.2.2. By Technology
17.18.2.3. By Vaccine
17.18.2.4. By End User
17.19. Japan
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Indication
17.19.2.2. By Technology
17.19.2.3. By Vaccine
17.19.2.4. By End User
17.20. South Korea
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Indication
17.20.2.2. By Technology
17.20.2.3. By Vaccine
17.20.2.4. By End User
17.21. GCC Countries
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Indication
17.21.2.2. By Technology
17.21.2.3. By Vaccine
17.21.2.4. By End User
17.22. South Africa
17.22.1. Pricing Analysis
17.22.2. Market Share Analysis, 2022
17.22.2.1. By Indication
17.22.2.2. By Technology
17.22.2.3. By Vaccine
17.22.2.4. By End User
17.23. Israel
17.23.1. Pricing Analysis
17.23.2. Market Share Analysis, 2022
17.23.2.1. By Indication
17.23.2.2. By Technology
17.23.2.3. By Vaccine
17.23.2.4. By End User
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Indication
18.3.3. By Technology
18.3.4. By Vaccine
18.3.5. By End User
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. GlaxoSmithKline Plc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.1.5.2. Product Strategy
19.1.1.5.3. Channel Strategy
19.1.2. Merck & Co. Inc
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.2.5.2. Product Strategy
19.1.2.5.3. Channel Strategy
19.1.3. Pfizer Inc.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.3.5.2. Product Strategy
19.1.3.5.3. Channel Strategy
19.1.4. Sanofi SA
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.4.5.2. Product Strategy
19.1.4.5.3. Channel Strategy
19.1.5. Panacea Biotec
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.5.5.2. Product Strategy
19.1.5.5.3. Channel Strategy
19.1.6. Zydus Cadila
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.6.5.2. Product Strategy
19.1.6.5.3. Channel Strategy
19.1.7. Emergent BioSolutions Inc
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.7.5.2. Product Strategy
19.1.7.5.3. Channel Strategy
19.1.8. Serum Institute of India Pvt. Ltd.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.8.5.2. Product Strategy
19.1.8.5.3. Channel Strategy
19.1.9. Bharat Biotech and Indian Immunological
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.9.5.2. Product Strategy
19.1.9.5.3. Channel Strategy
19.1.10. Catalent Inc
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.10.5.2. Product Strategy
19.1.10.5.3. Channel Strategy
19.1.11. Robinson Pharma, Inc.
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.11.5.2. Product Strategy
19.1.11.5.3. Channel Strategy
19.1.12. Hunan Er-Kang Pharmaceutical Co., Ltd.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.12.5.2. Product Strategy
19.1.12.5.3. Channel Strategy
19.1.13. Procaps
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.13.5.2. Product Strategy
19.1.13.5.3. Channel Strategy
19.1.14. CAPTEK Softgel International Inc.
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.14.5.2. Product Strategy
19.1.14.5.3. Channel Strategy
19.1.15. Softcaps, Fuji Capsule Co., Ltd.
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
19.1.15.5.2. Product Strategy
19.1.15.5.3. Channel Strategy
19.1.16. Aenova Holding GmbH
19.1.16.1. Overview
19.1.16.2. Product Portfolio
19.1.16.3. Profitability by Market Segments
19.1.16.4. Sales Footprint
19.1.16.5. Strategy Overview
19.1.16.5.1. Marketing Strategy
19.1.16.5.2. Product Strategy
19.1.16.5.3. Channel Strategy
19.1.17. Sirio Pharma Co., Ltd.
19.1.17.1. Overview
19.1.17.2. Product Portfolio
19.1.17.3. Profitability by Market Segments
19.1.17.4. Sales Footprint
19.1.17.5. Strategy Overview
19.1.17.5.1. Marketing Strategy
19.1.17.5.2. Product Strategy
19.1.17.5.3. Channel Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Paediatric Vaccine Market
